1 Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
2 Mayo Clinic Cancer Center, Rochester, MN.
AJR Am J Roentgenol. 2019 Aug;213(2):309-317. doi: 10.2214/AJR.19.21123. Epub 2019 Apr 30.
The purpose of this article is to enhance knowledge of the clinical implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of patients with neuroendocrine tumors. Most well differentiated and some moderately and poorly differentiated neuroendocrine tumors express large numbers of somatostatin receptors on their cell surfaces. PRRT targets these cells with Lu-DOTATATE, which is a medium-energy beta emitter. Since this agent received U.S. Food and Drug Administration approval in 2018, tremendous effort has been exerted at institutions throughout the United States toward proper implementation of this promising therapy. This review summarizes clinical implementation of PRRT and its impact on patient care.
本文旨在增强对肽受体放射性核素治疗 (PRRT) 的临床应用及其对神经内分泌肿瘤患者治疗的影响的认识。大多数高分化和一些中分化及低分化神经内分泌肿瘤的细胞表面表达大量生长抑素受体。PRRT 采用 Lu-DOTATATE 靶向这些细胞，Lu-DOTATATE 是一种中能 β 射线发射体。自该药物于 2018 年获得美国食品和药物管理局批准以来，美国各地的医疗机构都在努力规范应用这一有前途的治疗方法。本综述总结了 PRRT 的临床应用及其对患者治疗的影响。
